Mina Zhang

Mina Zhang

Auto-generated profile, based on publicly available information

Mina Zhang

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Shanghai, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2023 in Optik
Verified
Journal Article
Closed access
XZXianglin Zhou
Xianglin Zhou
LHLongjun He
Longjun He
MZMina Zhang
Mina Zhang
PWPeng Wang
Peng Wang

29 May 2022 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
MZMina Zhang
Mina Zhang
BLBo Lian
Bo Lian
RZRui Zhang
Rui Zhang
YGYuhong Guo
Yuhong Guo
JZJingxia Zhao
Jingxia Zhao
XXXiaolong Xu
Xiaolong Xu
Sepsis-induced inflammatory response leads to intestinal damage and secondary bacterial translocation, causing systemic infections and eventually death. Emodin is a natural anthraquinone derivative in many plants with promising bioactivities. However, the effects and mechanisms of emodin on sepsis-induced intestinal dysfunctions have not been well clarified yet. We found that emodin treatment suppressed the inflammatory response in the intestines of septic mice. Intestinal barrier function was also improved by emodin through enhancing ZO-1 and occludin expression, which prevented the secondary translocation of Escherichia coli. By proteome microarray investigation, JNK2 was identified as a direct target of emodin. In vitro study also showed that emodin inhibited LPS-induced inflammatory response in intestinal epithelial cells. Nuclear factors including NF-κB and AP-1 were further identified as downstream effectors of JNK2. Bioinformatic analysis based on 16s rRNA gene sequencing illustrated that emodin treatment significantly increased the alpha- and beta-diversity of gut microbiota in septic mice. Moreover, data according to functional prediction showed that emodin decreased the abundance of potential pathogenic bacteria in gut. Our findings have shown that emodin treatment prevented inflammatory induced barrier dysfunction and decreased the potential pathogenicity of lumen bacteria, reducing the hazard of lumen bacterial translocation during sepsis.

9 April 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XZXiaojuan Zhang
Xiaojuan Zhang
MZMina Zhang
Mina Zhang
XDXinyang Du
Xinyang Du
GZGuowei Zhang
Guowei Zhang
YNYuanyuan Niu
Yuanyuan Niu
HWHuijuan Wang
Huijuan Wang
Background: This study aims to determine the efficacy and safety profile of aumolertinib in the real-word treatment setting for advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations.Methods: We retrospectively analyzed the clinical data of 173 EGFR-mutated advanced NSCLC patients who received aumolertinib treatment at Henan Cancer Hospital from April 2020 to December 2022. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier survival curves, while a Cox regression model was used for multifactorial analysis and prognostic factor assessment.Results: Among patients administered first-line aumolertinib (n = 77), the objective remission rate (ORR) of 77.92% was observed, along with a disease control rate (DCR) of 100%. The median progression-free survival (mPFS) was 24.97 months, which did not reach the median overall survival (mOS). The patients treated with aumolertinib after progression on prior EGFR-tyrosine kinase inhibitor (TKI) therapy (n = 96) exhibited an ORR of 46.88%, a DCR of 89.58%, an mPFS of 15.17 months, and an mOS of 21.27 months. First-line treatment multivariate Cox regression analysis demonstrated a statistically significant impact of elevated creatine kinase on PFS (p = 0.016) and a similar significant influence of co-mutation on OS (p = 0.034). Furthermore, subsequent-line treatment multivariate Cox regression analysis showed a statistically significant impact of elevated creatine kinase on median PFS (p = 0.026) and a significant effect on the number of metastatic organs (p = 0.017), co-mutation (p = 0.035), and elevated creatine kinase (p = 0.014) on median OS.Conclusion: Aumolertinib has shown clinical significance and can safely be used in the real-world setting for patients with EGFR mutation-positive NSCLC.

18 November 2020 in Research Square
Verified
Preprint
Open access
PDF file
MZMina Zhang
Mina Zhang
LFLuda Feng
Luda Feng
SZShuwen Zhang
Shuwen Zhang
PJPing Jiang
Ping Jiang
NLNing Liang
Ning Liang
QLQingquan Liu
Qingquan Liu
Background: Severe pneumonia (SP) is a life-threatening condition without specific treatment options. Although there are many available treatment options for SP, most of the therapies have been associated with mild or severe side effects. The purpose of this meta-analysis is to examine the efficacy and safety of Xuebijing injection (XBJ), a Chinese patent approved by the China Food and Drug Administration, for treating patients with SP.Methods: An electronic and manual search of published articles, ongoing trials, dissertations, and grey literature will be performed. Electronic databases including Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang Data, SinoMed will be searched without language restrictions from their inception to 01/10/2020. All randomized controlled trials where (a) XBJ is compared with placebo or no treatment, (b) XBJ plus routine treatment is compared with routine treatment, and (c) XBJ plus co-interventions are compared with co-interventions will be included. Severe pneumonia-related mortality will be set as the primary outcome. Study inclusion, data extraction, and quality assessment will be independently performed by two reviewers. Review Manager 5.3 is to be used to perform the assessment of the risk of bias, data synthesis, and subgroup analysis. Grading of Recommendations Assessment, Development, and Evaluation approach will be used to evaluate the quality of the overall evidence. This protocol was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols.Discussion: This proposed systematic review and meta-analysis will identify and synthesise evidence to clarify efficacy and safety of XBJ for SP. The results will help provide the best available evidence to decision-makers.PROSPERO registration number: CRD42020181234